Business Context and Reporting Period
Cytomx Therapeutics, Inc. (CTMX) filed a Form 8-K on May 27, 2025, regarding a corporate governance event related to its listing status on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a Current Report under Item 8.01 (Other Events) and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the resolution of a Nasdaq listing deficiency:
- Previous Status: On February 24, 2025, the Company was notified of non-compliance with Nasdaq Listing Rule 5450(a)(1) due to a failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- Current Status: On May 27, 2025, Nasdaq staff notified the Company that it regained compliance. The closing price of the Common Stock was $1.00 or greater for the 10 consecutive trading days ended May 23, 2025.
- Outcome: The matter regarding the Minimum Bid Price Requirement is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks beyond the resolution of the specific listing compliance issue. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the current trading price of CTMX to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the Company's most recent 10-Q or 10-K for actual financial performance metrics, as this 8-K contains none.
- Confirm the effective date of the Nasdaq compliance determination (May 27, 2025) against market data.